林业发展局批准Opdivo和Yervoy对成人和青少年的某些高级直肠癌进行治疗。 FDA approves Opdivo and Yervoy for certain advanced colorectal cancers in adults and teens.

美国食品和药物管理局批准了Opdivo (nivolumob) 和Yervoy (ipilimumab) 组合治疗12岁及以上的成人和儿童,这些患者患有特定类型的晚期结直肠癌 (CRC),不匹配修复缺陷或微卫星不稳定性较高. The FDA has approved a combination of Opdivo (nivolumob) and Yervoy (ipilimumab) for treating adults and children aged 12 and older with specific types of advanced colorectal cancer (CRC) that are mismatch repair-deficient or have high microsatellite instability. 这一批准的依据是临床试验数据,该数据表明,与标准化疗相比,疾病增发或死亡显著减少。 This approval is based on clinical trial data that showed a significant reduction in disease progression or death compared to standard chemotherapy. 常见副作用包括疲劳症、腹泻和恶心。 Common side effects include fatigue, diarrhea, and nausea.